Pyrrolo[1,2-b] pyridazine derivatives

Patent metadata

Field	Value
Publication number	US-11535622-B2
Application number	US-202017110734-A
Country	US
Kind code	B2
Filing date	Dec 3, 2020
Priority date	Jul 13, 2018
Publication date	Dec 27, 2022
Grant date	Dec 27, 2022

Abstract

A compound of Formula (I):pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.

First claim

What is claimed is:

1. A method of treating an inflammatory condition selected from:
rheumatoid arthritis (RA), inflammatory bowel disease (IBD), gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjogren's syndrome, or, Psoriasis, in a patient in need thereof, comprising administering to said patient a compound of Formula (II):

or a pharmaceutically acceptable salt thereof, wherein:
R 1 is H, D or methyl, R 2 is H, D or methyl, or

R 1 and R 2 , together with the carbon atoms to which they are attached, form cyclopropyl.

2. The method of claim 1 wherein the condition is arthritis.

3. The method of claim 2 wherein the condition is RA.

4. The method of claim 1 wherein the condition is systemic lupus erythematosus.

5. The method of claim 1 wherein the condition is IBD.

6. The method of claim of 1 wherein the condition is pelvic inflammatory disease.

7. The method of claim 1 wherein the condition is Sjogren's syndrome.

8. The method of claim 1 wherein the condition is gout.

9. The method of claim 1 wherein the condition is Lyme disease.

10. The method of claim 1 wherein the condition is psoriasis.

11. A method of treating an inflammatory condition selected from rheumatoid arthritis (RA), inflammatory bowel disease (IBD), gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), or Sjogren's syndrome, in a patient in need thereof, comprising administering to said patient the compound

or a pharmaceutically acceptable salt thereof.

12. The method of claim 11 wherein the condition is arthritis.

13. The method of claim 12 wherein the condition is RA.

14. The method of claim 11 wherein the condition is systemic lupus erythematosus.

15. The method of claim 11 wherein the condition is IBD.

16. The method of claim 11 wherein the condition is pelvic inflammatory disease.

17. The method of claim 11 wherein the condition is Sjogren's syndrome.

18. The method of claim 11 wherein the condition is gout.

19. The method of claim 11 wherein the condition is Lyme disease.

20. The method of claim 11 wherein the condition is psoriasis.

21. A method of treating an inflammatory condition selected from rheumatoid arthritis (RA), inflammatory bowel disease (IBD), gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), or Sjogren's syndrome, in a patient in need thereof, comprising administering to said patient a pharmaceutical composition comprising the compound:

or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable excipient.

22. The method of claim 21 wherein the condition is arthritis.

23. The method of claim 22 wherein the condition if RA.

24. The method of claim 21 wherein the condition is systemic lupus erythematosus.

25. The method of claim 21 wherein the condition is IBD.

26. The method of claim 21 wherein the condition is pelvic inflammatory disease.

27. The method of claim 21 wherein the condition is Sjogren's syndrome.

28. The method of claim 21 wherein the condition is gout.

29. The method of claim 21 wherein the condition is Lyme disease.

30. The method of claim 21 wherein the condition is psoriasis.

Assignees

• Gilead Sciences Inc

Inventors

• Ammann Stephen
• Bacon Elizabeth M
• Brizgys Gediminas
• Chin Elbert
• Chou Chienhung
• Cottell Jeromy J
• Ndukwe Marilyn
• Taylor James G
• Wright Nathan E
• Yang Zheng-Yu
• Zipfel Sheila M

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/5025

  ortho- or peri-condensed with heterocyclic ring systems · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title